Alnylam, Vir team up to develop siRNAs to tackle COVID-19

Alnylam and Vir Biotechnology have teamed up to develop RNAi therapeutics against the coronavirus behind the COVID-19 outbreak. The collaboration builds on Alnylam synthesis of siRNAs that target highly conserved regions of coronavirus RNA.

Alnylam, Vir team up to develop siRNAs to tackle COVID-19
Alnylam and Vir Biotechnology have teamed up to develop RNAi therapeutics against the coronavirus behind the COVID-19 outbreak. The collaboration builds on Alnylam synthesis of siRNAs that target highly conserved regions of coronavirus RNA.